|
Interview
'We are the only country providing formal training for clinical trials'
Professor Christoph Thiemermann, CEO, William Harvey Research
Limited (WHRL), UK, gives an insight into WHRL's collaboration with CREMA (Clinical
Research Education and Management Academy) and more on international research
education trends and education in India, in conversation with Arshiya Khan
What
was the rationale behind WHRL's tie up with CREMA?
We are into clinical research and also teach medical students. When we were
approached by CREMA, we looked at the curriculum and felt that there was a need
for the course because none of us involved in clinical research had had formal
training. So we were medical directors or XYZ at some pharmacetuical company
and followed protocols as set by somebody else, so we had to learn how to do
it.
When I conducted clinical trials, I had juniors who could help me with the trials
but a lot of my time was spent on teaching them as they had no formal training.
So when we came to know that CREMA is going to teach doctors, nurses, accountants
and life science graduates and graduates in general, we found that very exciting.
Because once these students graduate, they can be picked up by the industry,
and they can start work from the first day itself, which saves a lot of time
and money for people like me. Also, the other thing is that there is no course
like this in the West. There are courses which run over a weekend or for three-four
days, and when you leave you are an expert in that small field. It is not available
in the UK and US also, and when we came to know that someone was doing this
course we wanted to be a part of it.
Will this collaboration give any accreditation to CREMA?
No. We will only provide guest lecture faculty to CREMA who are experts in their
field. These guest lectures may be from the Queen Mary University, London or
from the US or Europe. This will give an international label to the teaching
here in India. There may be faculty coming to provide lectures on ethics, somebody
who looks after the European Medical Agency etc. As far as accreditation is
concerned that's not something that we are talking about today, as it is a very
new course.
How will this collaboration progress and what will be the
frequency of the lectures?
We are going to be sending two or three people every year for a week at a time
to teach at every campus of CREMA i.e at Bangalore, Delhi and Mumbai. But the
number will vary as when the number of students goes up, more time will be needed.
What benefits does it give WHRL?
At the moment, there is a financial commitment but any profits that are made
would be used to do more research. Before the tie up with CREMA, we spoke to
pharma companies if they wanted to work with us in some way. What drew us to
CREMA is that CREMA is an Indian standard of teaching.. CREMA will train students
and so it gives us the way to contact, or to get in contact with a number of
small and large pharma companies in India. And this was our major motivation
in tying up with CREMA.
Does WHRL have any other similar tie ups with any other
institutions in other countries?
No. In terms of teaching, clinical teaching and clinical trial teaching we are
committed to CREMA and that's the only tie up we have. We conduct pre-clinical
contract research, we do contract research in any given year with about 20-30
different companies and that's all over the world. We have more biotech companies
and also big MNCs like GSK.
What is the reason for choosing India and CREMA?
There is no other organisation in India who offers this type of course in pre-clinical
trials. Though there are two other organisations in India doing something on
the same lines, we were contacted by CREMA. We got introduced to CREMA through
the British Council i.e UKTI office (UK Trade and Industry). We told them of
our interest to be involved in the clinical trial teaching arena and after negotiations
we finalised the deal.
Will the students trained at CREMA be placed in WHRL's
CRO?
There is no definitive agreement. It is not really a CRO in the sense that WHRL
doesn't do any clinical trials. We only do pre-clinical trials. So there is
no agreement in place that we would take all the students or they will be a
part. However if there is a trial going on and a student wishes to come to observe
and help in that trial at that time, then it is something that can be definitely
thought about.
Has the institution also tied up with any other research
institutes or government body, in India or else where in the world? Is there
any MoU in the pipeline?
No, this deal is exclusive in a way and we have no intentions of tying up with
other organisations in India to do clinical trial teaching.
Is the clinical research industry/education in India different
from that of Europe? What are the plus and minuses of the Indian Clinical Research
industry in terms of education? How can that be built upon?
I think the question should be turned around. There is no ethical pharma training
in Europe and in the absence of one I think we are leading. And in fact we are
the only country providing formal training for clinical trials. And unlike in
other countries where they have small certificate courses or computer based
training and they are certified. In UK it's the ICR (Institute of Clinical Research),
UK. In America, the American Clinical Research Professionals (ACRP), conducts
small time training programmes or computer based training programmes which are
later certified. After having realised the fact that clinical research is booming
and there is a new paradigm and new business, we have an advantage here as we
specifically train people to have the skills and attitude necessary for clinical
research as a profession.
Accreditation is quite difficult as they still have to familiarise themselves
with the teaching and the topic which they have not done in the past. So I think
accreditation will take place in future. There is also a possibility that CREMA
or another body in India could teach in Europe and or have similar courses.
A large number of clinical research training institutes
have mushroomed to take full advantage of the predicted boom in the clinical
research and trials industry. What will determine which institutes stand the
test of time and survive the competition?
We have many fly-by-night operators to start such courses. I think over the
last few years, there are very few established institutes and organisations.
We have CREMA, ICRI, and ACRP. Others are likely to do tie ups or will probably
merge or operate in certain regions, not at an all India level. Secondly, people
who will stay in the industry are people who have started with a clear vision
and a mission of ensuring that you are at the finishing school. And for people
who come from other institutes and wish to be employed with this organisation
are those who have missed that finishing touch. So ideally organisations like
CREMA who serve as a medium between the industry and the academia are here to
stay.
What are your future plans in terms of evolving new courses,
specialisations? Which areas would they be focused on?
We recognise that clinical research is a booming industry. And therefore we
went ahead and started with clinical research project management, data management,
pharmacovigilance, medical writing and clinical trial supplies management. And
all of these are getting to be recognised as separate identities requiring special
skills. Therefore we are starting with special courses. But these five streams
are the ones that we will focus on before we move on. Since we don't have the
benefit of existing US or UK based learning programmes, we will start sharing
practices with India and say that this is what we require and then exchange
notes with others.
What are the international trends in clinical research
education/training?
Internationally also we will be looking at the core areas mentioned above. But,
India started its foray into outsourced work doing only medical transcription
earlier during 2002-2005. We moved on being a Business Process Outsourcing (BPO)
organisation doing minimal value add work till recently. We are now considered
and acclaimed for medical writing and pharmacovigilance, a definite value addition
- KPO a Knowledge Process Outsourcing organisation.
arshiya.khan@expressindia.com
|